Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Transition set to acquire NeuroMedix
Under the offer, valued at $11.1 million, NeuroMedix common shareholders can receive one common share of Transition for every 5.1429 NeuroMedix common shares tendered. The company's directors, officers
Under the offer, valued at $11.1 million, NeuroMedix common shareholders can receive one common share of Transition for every 5.1429 NeuroMedix common shares tendered. The company's directors, officers
The drug is an anthrax immune globulin (AIG) therapeutic treatment for patients who present with symptoms of anthrax disease resulting from the release of anthrax toxins into the
The biopharmaceutical firm said the offering would raise up to $86.25 million, although the company has not revealed how many shares it is planning to sell in the
The study, published in the journal Molecular Psychiatry, compared genetic variants in individuals with schizophrenia to individuals who do not have the disease. Sequencing revealed specific genetic variants
In addition to the RSV collaboration, the biopharmaceutical firm is working with the institute on the clinical development of HIV and influenza vaccines. “Data emerging from the clinical
Californian biopharmaceutical company Pain Therapeutics’ initial phase I study is designed to evaluate the pharmacokinetics of a proprietary radio-labeled monoclonal antibody in patients diagnosed with metastatic melanoma. The
Riquent is being developed to specifically treat lupus renal disease by preventing or delaying renal flares. A lupus renal flare is a potentially life-threatening increase in inflammation targeting
Over 800 patients with mild Alzheimer's disease enrolled in the study will take 800 mg twice daily of either Flurizan or placebo and attend periodic physician visits for
Ramelteon works by acting on receptors which regulate the body's sleep-wake cycle, while other insomnia treatments work by depressing the central nervous system. Ramelteon was approved by the
Prograf is currently approved for the prevention of kidney, liver and heart transplant recipients in the US. The FDA sent Japanese company Astellas an approvable letter over concerns